NCT00423332 - Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

October 31, 2016

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Cediranib

45 mg oral tablet

DRUG

Cediranib Placebo

oral tablet

Trial Locations (8)

Research Site, Groningen

Research Site, Leiden

Research Site, Nijmegen

Research Site, Birmingham

Research Site, London

Research Site, Manchester

Research Site, Northwood

Research Site, Oxford